ARK Genomic Revolution ETF
ARKG
333 hedge funds and large institutions have $628M invested in ARK Genomic Revolution ETF in 2022 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 71 increasing their positions, 132 reducing their positions, and 87 closing their positions.
2.73% less ownership
Funds ownership: 29.41% → 26.68% (-2.7%)
12% less call options, than puts
Call options by funds: $83.9M | Put options by funds: $95M
14% less funds holding
Funds holding: 387 → 333 (-54)
42% less capital invested
Capital invested by funds: $1.09B → $628M (-$462M)
46% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 132
59% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 87
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
Top Sellers
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$45.9M |
| 2 |
Goldman Sachs
New York
|
-$41.3M |
| 3 |
Morgan Stanley
New York
|
-$26.3M |
| 4 |
EP
Eversept Partners
New York
|
-$21.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$17.6M |
ARKG Hedge Fund Activity: Q2 2022 in Review
333 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q2 2022, worth a combined $628M — down 42% from $1.09B a quarter earlier.
Sellers outnumbered buyers: 87 funds closed out of ARKG and 36 opened new positions — a net loss of 51 holders — while 132 trimmed existing stakes and 71 added.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $26.2M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $45.9M sold.
- 333 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q2 2022, down from 387 in Q1 2022.
- Funds reported $628M of ARK Genomic Revolution ETF stock for Q2 2022, down 42% quarter-over-quarter.
- 36 funds opened new ARK Genomic Revolution ETF positions in Q2 2022 and 87 closed out, a net change of -51 holders.
- The largest ARK Genomic Revolution ETF buyer in Q2 2022 was Avidity Partners Management, an estimated $26.2M added.
- The largest ARK Genomic Revolution ETF seller in Q2 2022 was Matrix Capital Management Company, an estimated $45.9M sold.
Based on aggregated 13F filings for Q2 2022.